产品名称 Anti-Human CD19 scFv Antibody (FMC63) 产品规格 100ug 有效成分含量 100% 是否进口 否 用途范围 仅供科研使用 产品类型 抗体 储存条件 在2至8°C下储存 保质期 12个月 产地 France 配送方式 物流 可售卖地 北京;天津;河北;山西;内蒙古;辽宁;吉林;黑龙江;上海;江苏;浙江;安徽;福建;江...
抗CD19 CAR慢病毒/Anti-CD19 CAR Lentivirus是不能复制的、基于HIV的VSV-G假型慢病毒颗粒,可以转导大多数哺乳动物细胞,包括原代细胞和非分裂细胞。这些病毒转导与第二代CAR(嵌合抗原受体)连接的抗CD19(克隆FMC63)的ScFv部分,该部分包含CD8铰链、4-1BB和CD3ζ信号结构域。慢病毒还含有嘌呤霉素选择标记物。 艾美...
Anti-CD19 hCAR-T细胞(scFv·CD3Z)产品信息产品说明书 相关数据产品订购产品名称: * 产品备注: * 称呼: * 联系电话: * 电子信箱: * 验证码: *基因&粒 现货质粒 质粒定制 病毒包装 现货病毒产品 病毒包装 细胞株 现货稳转细胞株 细胞株定制 CAR-T 现货CAR病毒液 CAR定制 服务 技术服务 科研服务 ...
继高亲和力人CD19蛋白之后,ACROBiosystems持续发力推出特异性靶向FMC63 scFv抗原识别表位的抗独特型抗体,进一步丰富了FMC63 CAR的检测手段。此抗体同高亲和力人CD19蛋白一样具有灵敏度高,特异性好的特点,经充分验证可适用于Flow Cytometry (FCM)方法检测Anti-CD19 (FMC63) CAR的表达。 产品特点: 能够高特异无背景...
A composition is provided that includes an anti-CD19 single chain variable fragment (scFv) conjugated to a tumor-associated antigen. The antigen can comprise a Her-2/neu protein, such as a Her-2/neu extracellular domain. Methods of eliciting an immune response are also provided along with ...
VGT-930-18C1 Anti-CD19 hCAR-T细胞(scFv·CD3Z) 1E7 细胞 询价 3～4周 VGT-930-18C2 Anti-CD19 hCAR-GFP-T细胞(scFv·hCD28Z) 1E7 细胞 询价 3～4周 VGT-930-18C3 Anti-CD19 hCAR-GFP-T细胞(scFv·hCD2841BBZ) 1E7 细胞 询价 3～4周 VGT-930-18E3 Anti-CD19 hCAR-CD19xCD3-T细胞 1E7...
which has been validated to be effective and safe to treat B-ALL, CLL, and B cell lymphoma. FMC63 is an IgG2a mouse monoclonal antibody targeting CD19. So far, most of reported CART19 trials contain the anti-CD19 scFv derived from FMC63, including the two FDA-approved CARs Kymriah and...
To demonstrate the universality of our CAR/CCR approach, we performed similar in vitro experiments with CAR (2nd Gen) and CAR/CCR T cells in which the anti-CD19 scFv binding domain of the CAR construct was replaced with a single chain specific for CD20 (Figure S3B). When co-cultured wit...
APC-labeled monoclonal anti-FMC63 scFv antibody、PE-Labeled Human CD19(20-291)Protein均以1:50比例加入293T-CAR19细胞EP管内,室温标记30min。 国内某知名品牌不同检测方法 FITC、PE、APC实验数据图 合佑生生物Anti-FMC63抗体 PE、APC不同标记数据图 ...
We hypothesized that a novel anti-CD19 scFv that engages an alternative CD19 membrane-proximal epitope independent of FMC63 and that is characterized by faster on- and off-rates could mitigate CART19 failure and improve clinical efficacy. Methods We developed an autologous CART19 product with 4-...